Journal
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
Volume 52, Issue 4, Pages -Publisher
WILEY
DOI: 10.1111/eci.13710
Keywords
antisense oligonucleotides; cardiovascular risk; Lipoprotein(a); oxidized phospholipids
Funding
- Hellenic Atherosclerosis Society
Ask authors/readers for more resources
The article summarizes the data on OxPLs and cardiovascular risk, as well as the impact of hypolipidemic medications on Lp(a) and OxPLs.
Over the past few years, there has been an undiminished interest in lipoprotein(a) [Lp(a)] and oxidized phospholipids (OxPLs), mainly carried on this lipoprotein. Elevated Lp(a) has been established as an independent causal risk factor for cardiovascular disease. OxPLs play an important role in atherosclerosis. The main questions that remain to be answered, however, is to what extent OxPLs contribute to the atherogenicity of Lp(a), what effect hypolipidaemic medications may have on their levels and the potential clinical benefit of their reduction. This narrative review aimed to summarize currently available data on OxPLs and cardiovascular risk, as well as the effect of established and emerging hypolipidaemic medications on Lp(a)-OxPLs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
